(MENAFN- Credence Research) The latest market report published by Credence Research, Inc. “Radiodermatitis Market By Product (Topical, Dressing, Oral) - Growth, Future Prospects, Competitive Analysis, 2017 - 2025,” The global radiodermatitis market was valued at US$ 295.5 million in 2016 and is expected to reach US$ 430.9 million by 2025 with a CAGR increase of 4.18 per cent from 2017 to 2025.
Browse the full report at https://www.credenceresearch.com/report/radiodermatitis-market
Market Insights
According to a report published in the European Oncology Nursing Society in 2016, as many as 95 per cent of oncology patients who opt for radiation therapy will experience some degree of skin reactions due to radiation therapy. Currently, there is no evidence to support any drugs present to prevent radiodermatitis. Some general guidelines have been considered for the effective management of radiodermatitis in oncology patients previously undergoing radiation therapy, such as gentle washing and drying, and topical moisturizers should be used prior to radiation therapy. Additionally, normal hygiene practices such as the use of mild detergent, deodorants not to be used in the exposed area and smoking should be avoided.
In 2016, the top-level segment held the largest market share due to key drivers, such as corticosteroids, is considered to be the gold standard for the treatment of radiodermatitis and increasing demand for hydrophilic creams that have been effective in overcoming patients ' discomfort by providing moisture to the dry skin desquamation area. Dressings will be the fastest growing segment during the 2017-2025 forecast period, mainly due to factors such as increasing oncology in patients opting for radiation therapy, a wide range of dressings available for the degree of skin complications due to radiation therapy. Technology advancements with hydrocolloid and hydrogel coatings are finding tremendous applications as they are used for the management of moist desquamation in order to promote a moist environment to facilitate re-epithelisation.
Download Free PDF Sample Request: https://www.credenceresearch.com/sample-request/58693
In 2016, North America held the largest revenue share mainly due to factors such as rising prevalence of radiodermatitis, affordable reimbursement scenario and existence of developed research and healthcare institutions. Asia Pacific will be the fastest growing market throughout the forecast period 2017-2025, majorly due to factors such as rising prevalence of radiodermatitis, competitive market due to presence of existing and budding manufacturers involved in the palliative treatment of radiodermatitis, increasing disposable incomes in these regions and flourishing online market for the sale of medication for radiodermatitis treatment.
The major players in radiodermatitis market are Acelity, Alliqua Biomedical, BMG Pharma S.R.L., Convatec, Inc., Derma Sciences, Inc., Intermed Pharmaceuticals, Molnlycke Health Care AB, Smith & Nephew plc, Stratpharma AG and 3M Healthcare.
Key Market Movements:
Rising demand for radiation therapy among the oncology patients
Merger and acquisition between healthcare industries has resulted in the expansion of product portfolio for radiodermatitis treatment
Supportive regulatory environment for radiodermatitis drugs
Affordable reimbursement scenario for the treatment of radiodermatitis in developed countries
By Product Type
Topical
Antibiotics
Hydrophilic Creams
Corticosteroids
Others
Dressing
No String Barrier Films
Honey Impregnated Gauze
Hydrogel and Hydrocolloid Dressings
Silicone Coated Dressings
Others
Oral
By Geography Segment
North America
Europe
Asia Pacific (APAC)
Middle East & Africa (MEA)
Latin America
Do Inquiry before buying report at https://www.credenceresearch.com/inquiry-before-buying/58693
MENAFN1909201900709442ID1099023746
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.